TherapeuticsMD (TXMD) EV to EBITDA (2011 - 2026)

TherapeuticsMD (TXMD) has reported EV to EBITDA for 16 consecutive years, with 20.09 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA fell 89.74% year-over-year to 20.09; the trailing twelve-month figure through Jun 2026 stood at 4.15 (down 112.02% YoY), and the FY2025 full-year result was 2.59, down 226.18% from the prior year.
• EV to EBITDA rose to 20.09 in Q2 2026 per TXMD's latest filing, from 20.69 in the prior quarter.
• Across five years, EV to EBITDA topped out at 0.15 in Q4 2022 and bottomed at 20.69 in Q1 2026.
• Historically, EV to EBITDA has averaged 9.43 across 5 years, with a median of 7.5 in 2022.
• The sharpest annual moves came in 2022 and 2023: EV to EBITDA surged 99.93% in 2022, then slumped 9213.16% in 2023.
• Over 5 years, EV to EBITDA stood at 0.15 in 2022, then plunged by 9213.16% to 14.31 in 2023, then soared by 47.92% to 7.45 in 2024, then gained by 1.58% to 7.33 in 2025, then sank by 173.86% to 20.09 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 20.09, 20.69, and 7.33 for Q2 2026, Q1 2026, and Q4 2025 respectively.